Combining either approach with polyclonal CD8+ T cells and a PD-L1 blocker (avelumab) may enrich the immune microenvironment by expanding molecular immune targets, allowing for anti-tumor T cell activation (NCT02584829). Here, CD274 is linked to neoplasm.